Rimiterol: Difference between revisions
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +)) |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 34: | Line 34: | ||
'''Rimiterol''' ([[International Nonproprietary Name|INN]]/[[United States Adopted Name|USAN]]) is a third-generation [[beta2-adrenergic receptor agonist|β<sub>2</sub>-agonist]]. | '''Rimiterol''' ([[International Nonproprietary Name|INN]]/[[United States Adopted Name|USAN]]) is a third-generation [[beta2-adrenergic receptor agonist|β<sub>2</sub>-agonist]]. | ||
==References== | |||
{{Reflist|2}} | |||
{{Asthma and copd rx}} | {{Asthma and copd rx}} | ||
[[Category:Beta-adrenergic agonists]] | [[Category:Beta-adrenergic agonists]] | ||
[[Category:Drug]] | |||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Latest revision as of 16:53, 13 April 2015
{{Drugbox | IUPAC_name = 4-{(S)-hydroxy[(2R)-piperidin-2-yl]methyl}benzene-1,2-diol | image = Rimiterol.svg | CAS_number = 32953-89-2 | CAS_supplemental = | ATC_prefix = R03 | ATC_suffix = AC05 | ATC_supplemental = | PubChem = 36283 | DrugBank = | chemical_formula = | C=12 | H=17 | N=1 | O=3 | molecular_weight = 223.268 g/mol | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = }} Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Rimiterol (INN/USAN) is a third-generation β2-agonist.